All Drug Development articles
-
NewsSandoz partners with Samsung Bioepis to accelerate biosimilar pipeline
New licensing, development and commercialisation agreement could expand Sandoz’s pipeline by to up to 32 assets.
-
NewsUpcycled plastic could facilitate production of Parkinson’s drug
Bioengineered E.coli provide an eco alternative to creating L-DOPA from terephthalic acid, suggests study.
-
NewsSana's islet cell transplant therapy shows early promise in type 1 diabetes
Biotech company’s long-term data demonstrated hypoimmune (HIP)-modified islet transplantation without immunosuppression in type 1 diabetes.
-
NewsGSK grants rare disease firm Alfasigma rights to linerixibat for $690m
Licence agreement with the Italy-based pharma company to advance GSK’s ambitions in rare disease.
-
NewsFDA revises PK study approach in new biosimilar draft guidance
Sandoz is also adjusting its global strategy by recruiting Armin Metzger as President of Biosimilar Development, Manufacturing & Supply.
-
NewsServier deepens rare oncology commitment with $2.5bn Day One acquisition
The deal aligns with the biopharma company’s goal of expanding its oncology pipeline by the end of the decade.
-
NewsSanofi gains access to first-in-class JAK inhibitor through $1.5bn licensing deal
Oral small molecule therapy rovadicitnib from Sino Biopharmaceutical offers potential to advance the pharma company’s haematology portfolio.
-
ReportPharma Horizons: Trends in Pharmaceutical Manufacturing
EPR’s 2026 pharma manufacturing trends report covers the key developments in supply chain, quality, drug development, new modalities and beyond.
-
NewsUCB signs $1.1bn to autoimmune collaboration with Chinese biotech Antengene
License agreement involves development of ATG-201, a B cell-depleting bispecific T-cell engager, supporting the biopharma company’s immunology pipeline.
-
NewsLipid nanoparticle discovery could increase drug delivery efficiency
Study findings offer potential to accelerate development of RNA-based medicines.
-
NewsNovo Nordisk strikes $2.1bn oral obesity biologic deal with Vivtex
Drug delivery partnership to advance next-generation oral therapies and help Novo Nordisk expand its obesity and diabetes portfolio.
-
NewsGSK acquires TGF-beta protein firm 35Pharma for nearly $1bn
Acquisition will help GSK scale its pipeline for respiratory, immunology and inflammatory diseases.
-
NewsAbbVie invests $380m in Illinois to expand US API manufacturing
Decision forms part of the pharma company’s plan to commit $100 billion to its R&D capabilities in the US over the next decade.
-
ArticleApplying AI to enhance drug formulation and development
AI/ML is not replacing formulation scientists or process engineers; it is just amplifying their expertise.
-
NewsFDA drafts new ultra-rare disease therapy guidance
Agency’s planned framework is the first to support the approval process for new ultra-rare disease treatments.
-
NewsGilead adds to cell therapy portfolio with $8bn acquisition of Arcellx
Deal builds on the companies’ 2022 collaboration over CAR T therapy anito-cel.
-
NewsLilly's Omvoh demonstrates long-term potential in Crohn’s
New late-stage data shows the drug enabled the majority of IBD patients to stay steroid free over three years of Omvoh treatment.
-
NewsDaiichi Sankyo picks Dr John Tsai to head up R&D
The ex-Novartis drug development head will lead the pharmaceutical company’s global R&D operations.
-
NewsRecipharm sells manufacturing site to Scinai in biologics collaboration
Recipharm forms a long-term partnership with the Israeli biopharma and CDMO covering early development through to commercial supply.
-
NewsPfizer’s Braftovi improves progression-free survival in colorectal cancer
A triple therapy combination of the drug could offer a “potentially practice-changing treatment option”, according to new late-stage data.